These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 20230061

  • 1. Origins of resistance to the HIVgp41 viral entry inhibitor T20.
    McGillick BE, Balius TE, Mukherjee S, Rizzo RC.
    Biochemistry; 2010 May 04; 49(17):3575-92. PubMed ID: 20230061
    [Abstract] [Full Text] [Related]

  • 2. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K, Shishido A, Root MJ.
    J Biol Chem; 2009 Feb 06; 284(6):3619-27. PubMed ID: 19073602
    [Abstract] [Full Text] [Related]

  • 3. The binding mode of fusion inhibitor T20 onto HIV-1 gp41 and relevant T20-resistant mechanisms explored by computational study.
    Qiu S, Yi H, Hu J, Cao Z, Wu Y, Li W.
    Curr HIV Res; 2012 Mar 06; 10(2):182-94. PubMed ID: 22339124
    [Abstract] [Full Text] [Related]

  • 4. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X, Zhang X, Chong H, Zhu Y, Wei H, Wu X, He J, Wang X, He Y.
    J Virol; 2017 Sep 15; 91(18):. PubMed ID: 28659478
    [Abstract] [Full Text] [Related]

  • 5. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S, Borrego P, Ding X, Zhu Y, Martins A, Chong H, Taveira N, He Y.
    J Virol; 2017 Jan 01; 91(1):. PubMed ID: 27795437
    [Abstract] [Full Text] [Related]

  • 6. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A, Biron Z, Arshava B, Scherf T, Naider F, Anglister J.
    FEBS J; 2015 Dec 01; 282(24):4643-57. PubMed ID: 26432362
    [Abstract] [Full Text] [Related]

  • 7. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L, Tong P, Yu X, Pan C, Zou P, Chen YH, Jiang S.
    Biochim Biophys Acta; 2012 Dec 01; 1818(12):2950-7. PubMed ID: 22867851
    [Abstract] [Full Text] [Related]

  • 8. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
    Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, Sanders RW, Berkhout B.
    J Virol; 2008 Jul 01; 82(13):6678-88. PubMed ID: 18434391
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y, Chong H, Qiu Z, Xiong S, He Y.
    J Virol; 2015 Jun 01; 89(11):5801-11. PubMed ID: 25787278
    [Abstract] [Full Text] [Related]

  • 10. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L, Gochin M, Liu K.
    Curr Top Med Chem; 2011 Dec 01; 11(24):2959-84. PubMed ID: 22044229
    [Abstract] [Full Text] [Related]

  • 11. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y, Ding X, Yu D, Chong H, He Y.
    J Virol; 2019 Dec 12; 94(1):. PubMed ID: 31619552
    [Abstract] [Full Text] [Related]

  • 12. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
    Lawless MK, Barney S, Guthrie KI, Bucy TB, Petteway SR, Merutka G.
    Biochemistry; 1996 Oct 22; 35(42):13697-708. PubMed ID: 8885850
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
    Wu X, Liu Z, Ding X, Yu D, Wei H, Qin B, Zhu Y, Chong H, Cui S, He Y.
    J Virol; 2018 Apr 01; 92(7):. PubMed ID: 29321334
    [Abstract] [Full Text] [Related]

  • 14. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M.
    J Virol; 2005 Jan 01; 79(2):764-70. PubMed ID: 15613304
    [Abstract] [Full Text] [Related]

  • 15. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
    Yuan C, Wang JY, Zhao HJ, Li Y, Li D, Ling H, Zhuang M.
    Retrovirology; 2019 Dec 03; 16(1):36. PubMed ID: 31796053
    [Abstract] [Full Text] [Related]

  • 16. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
    Gonzalez E, Ballana E, Clotet B, Esté JA.
    AIDS; 2011 Aug 24; 25(13):1557-83. PubMed ID: 21572303
    [Abstract] [Full Text] [Related]

  • 17. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y, Chong H, Xiong S, Qiao Y, Qiu Z, He Y.
    J Virol; 2015 Dec 24; 89(24):12467-79. PubMed ID: 26446597
    [Abstract] [Full Text] [Related]

  • 18. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
    He Y, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q.
    Proc Natl Acad Sci U S A; 2008 Oct 21; 105(42):16332-7. PubMed ID: 18852475
    [Abstract] [Full Text] [Related]

  • 19. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M.
    New Microbiol; 2004 Apr 21; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [Abstract] [Full Text] [Related]

  • 20. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
    Jenwitheesuk E, Samudrala R.
    Antivir Ther; 2005 Apr 21; 10(8):893-900. PubMed ID: 16430194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.